Pet Pharm Biotech Co., Ltd. (TPEX: 7762)
Health Care · Biotechnology · TW
NT$51.20
+2.50% today · -28.2% 1Y
Pet Pharm Biotech Co., Ltd. (TPEX: 7762) operates in the Biotechnology industry within the Health Care sector. The company is valued at $92.96M.
Over the last twelve months the share price has lost 28.2%, trading between 44.00 and 89.85.
Tweenvest scores Pet Pharm Biotech Co., Ltd. across four factors: quality 66/100, value 73/100, dividend 33/100. Its strongest factor is value.
7762 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $92.96M
- Revenue (TTM)
- $8.35M
- P/E
- 99.46
- EPS
- 0.45
- Dividend yield
- 0.48%
- Beta (5Y)
- 0.62
- 52-week high
- NT$89.85
- 52-week low
- NT$44.00
- Avg volume (3M)
- —
- Shares outstanding
- 58.09M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $262.42 | -1.27% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.10 | -0.48% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.70 | -0.05% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $549.79 | -0.55% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $822.15 | -1.37% |
| argenx SEENXTBR: ARGX | $64.17B | €889.60 | +1.18% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $149.44 | -5.91% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.